• 1
    Cohn SM,Schloemann S,Tessner T,Seibert K,Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest 1997; 99: 136779.
  • 2
    Smith WL,Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 14915.
  • 3
    Chandrasekharan NV,Dai H,Roos KL,Evanson NK,Tomsik J,Elton TS,Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 1392631.
  • 4
    Wolff H,Saukkonen K,Anttila S,Karjalainen A,Vainio H,Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 49975001.
  • 5
    Tucker ON,Dannenberg AJ,Yang EK,Zhang F,Teng L,Daly JM,Soslow RA,Masferrer JL,Woerner BM,Koki AT,Fahey TJ,III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 98790.
  • 6
    Parrett ML,Harris RE,Joarder FS,Ross MS,Clausen KP,Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 5037.
  • 7
    Liu CH,Chang SH,Narko K,Trifan OC,Wu MT,Smith E,Haudenschild C,Lane TF,Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 185639.
  • 8
    Jacoby RF,Seibert K,Cole CE,Kelloff G,Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 50404.
  • 9
    Reddy BS,Hirose Y,Lubet R,Steele V,Kelloff G,Paulson S,Seibert K,Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 2937.
  • 10
    Gupta S,Adhami VM,Subbarayan M,MacLennan GT,Lewin JS,Hafeli UO,Fu P,Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 333443.
  • 11
    Fischer SM,Lo HH,Gordon GB,Seibert K,Kelloff G,Lubet RA,Conti CJ. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25: 23140.
  • 12
    Harris RE,Alshafie GA,Abou-Issa H,Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 21013.
  • 13
    Kubatka P,Ahlers I,Ahlersova E,Adamekova E,Luk P,Bojkova B,Markova M. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 2003; 202: 1316.
  • 14
    Steinbach G,Lynch PM,Phillips RK,Wallace MH,Hawk E,Gordon GB,Wakabayashi N,Saunders B,Shen Y,Fujimura T,Su LK,Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 194652.
  • 15
    Bertagnolli MM,Eagle CJ,Zauber AG,Redston M,Solomon SD,Kim K,Tang J,Rosenstein RB,Wittes J,Corle D,Hess TM,Woloj GM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 87384.
  • 16
    Harris RE,Beebe-Donk J,Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27.
  • 17
    Zhang X,Chen ZG,Choe MS,Lin Y,Sun SY,Wieand HS,Shin HJ,Chen A,Khuri FR,Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005; 11: 62619.
  • 18
    Sawaoka H,Kawano S,Tsuji S,Tsujii M,Gunawan ES,Takei Y,Nagano K,Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G10617.
  • 19
    Fu SL,Wu YL,Zhang YP,Qiao MM,Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004; 10: 19714.
  • 20
    Csiki I,Morrow JD,Sandler A,Shyr Y,Oates J,Williams MK,Dang T,Carbone DP,Johnson DH. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005; 11: 663440.
  • 21
    Prince HM,Mileshkin L,Roberts A,Ganju V,Underhill C,Catalano J,Bell R,Seymour JF,Westerman D,Simmons PJ,Lillie K,Milner AD, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 550414.
  • 22
    Ushiyama S,Yamada T,Murakami Y,Kumakura S,Inoue S,Suzuki K,Nakao A,Kawara A,Kimura T. Preclinical pharmacology of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Eur J Pharmacol, Sep 11, 2007, (Epub ahead of print).
  • 23
    Moberly JB,Harris SI,Riff DS,Dale JC,Breese T,McLaughlin P,Lawson J,Wan Y,Xu J,Truitt KE. A randomized double-blind one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. Dig Dis Sci 2007; 52: 44250.
  • 24
    Rohatagi S,Kastrissios H,Truitt1 K,Moberly J,Wada R,Salazar D. Pain relief model for a Cox-2 inhibitor in patients with post-operative dental pain, Submitted for publication.
  • 25
    Yonekura K,Basaki Y,Chikahisa L,Okabe S,Hashimoto A,Miyadera K,Wierzba K,Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: 218591.
  • 26
    Goi T,Fujioka M,Satoh Y,Tabata S,Koneri K,Nagano H,Hirono Y,Katayama K,Hirose K,Yamaguchi A. Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor. Cancer Res 2004; 64: 190610.
  • 27
    Kiriakidis S,Andreakos E,Monaco C,Foxwell B,Feldmann M,Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 116: 66574.
  • 28
    Hsu AL,Ching TT,Wang DS,Song X,Rangnekar VM,Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397403.
  • 29
    Wu GS,Zou SQ,Liu ZR,Tang ZH,Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003; 9: 13026.
  • 30
    Kaur BS,Khamnehei N,Iravani M,Namburu SS,Lin O,Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 607.
  • 31
    Cui W,Yu CH,Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 821314.
  • 32
    Patel MI,Subbaramaiah K,Du B,Chang M,Yang P,Newman RA,Cordon-Cardo C,Thaler HT,Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 19992007.
  • 33
    Waskewich C,Blumenthal RD,Li H,Stein R,Goldenberg DM,Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 62: 202933.
  • 34
    Tsujii M,Kawano S,DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 333640.
  • 35
    Masferrer JL,Leahy KM,Koki AT,Zweifel BS,Settle SL,Woerner BM,Edwards DA,Flickinger AG,Moore RJ,Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 130611.
  • 36
    Lin HI,Chu SJ,Wang D,Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect 2004; 37: 815.
  • 37
    Lehmann JM,Lenhard JM,Oliver BB,Ringold GM,Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 340610.
  • 38
    Mahadevan V,Hart IR. Tumour angiogenesis and metastasis. Eur J Cancer 1991; 27: 67980.
  • 39
    Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer 1995; 31: 11014.
  • 40
    Oitate M,Hirota T,Koyama K,Inoue S,Kawai K,Ikeda T. Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 2006; 34: 141722.
  • 41
    Tanaka Y,Eda H,Tanaka T,Udagawa T,Ishikawa T,Horii I,Ishitsuka H,Kataoka T,Taguchi T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 1990; 50: 22905.
  • 42
    Lorite MJ,Cariuk P,Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997; 76: 103540.